FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Visa Unveils Tool to Strengthen Agentic Commerce for Firms

New offering aims to simplify and enhance digital commerce capabilities.Highlights: Visa launches a new tool for agentic commerce.The...
FinTech

AI Citing Bolt Lays Off a Third of Staff

The tech company streamlines operations amidst shifting market conditions.Highlights: Bolt reduces workforce by a third due to AI...
FinTech

MillTech Secures $60 Million to Expand into US Market

Funding positions MillTech for growth in North America.Highlights: MillTech raises $60 million for US expansion.The funding aims to...
FinTech

KreditBee Joins Unicorn Club After $280 Million Funding Round

Fintech firm KreditBee reaches unicorn status with significant investor backing.Highlights: KreditBee raises $280 million in Series D funding.Company...